-
Mashup Score: 25Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine - 4 month(s) ago
Key Points. Patients in remission treated with Oral-AZA had better OS and RFS vs placebo regardless of NPM1 or FLT3 mutational status at AML diagnosis.Oral
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60
The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.’s business for stockholders, potential investors, and financial analysts.
Source: ir.syndax.comCategories: General Medicine News, Hem/OncsTweet-
It was an honor to present interim results of Aza/Ven + Revumenib in newly Dx older AML pts with NPM1 mut or KMT2Ar on behalf of my co-authors & @LLSusa @EHA_Hematology. Regimen is highly active & hopeful this can make a huge impact in #AML @UNC_Lineberger https://t.co/G7FXFO2eXf https://t.co/HfaAOThdY2
-
-
Mashup Score: 48PHASE 1B STUDY OF AZACITIDINE, VENETOCLAX AND REVUMENIB IN NEWLY... by Dr. Joshua Zeidner - 6 month(s) ago
EHA Library; Zeidner J. Jun 13 2024; 422238;
Source: library.ehaweb.orgCategories: General Medicine News, Hem/OncsTweet-
Looking forward to presenting a phase 1 study of Azacitidine, Venetoclax and Revumenib in newly Dx AML w/ NPM1 mut or KMT2A rearrangement @EHA_Hematology. Canāt wait for the exciting Menin Inhibitor oral Session! @LLSusa @UNC_Lineberger https://t.co/Fwg3r30s2n
-
-
Mashup Score: 0
Donāt miss whatās happeningPeople on X are the first to know.Log inSign upSettingsPostJoshua Zeidner MD@LeukDocJZAnother successful Leukemia Journal Club @UNC_Lineberger. We dissected the AGILE study as well as subset analyses of IDH1 mut #AML from VIALE-A. We even had a special guest appearance. Having great colleagues makes all the difference @danielrich21@justinhreid@KatieBPharmD12:51 AM Ā· Feb…
Source: x.comCategories: General Medicine News, Hem/OncsTweet-
Awesome! Great mindsā¦ https://t.co/uSKZoFu9dh https://t.co/3DJ2YwpTn0
-
-
Mashup Score: 29
OffLabel Disclosure:. Borate:RUNX1 Foundation: Honoraria; Servier: Membership on an entity’s Board of Directors or advisory committees; Kura: Membership on an e
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Agree- such an important issue impacting clinical practice. But we need prospective data to guide these decisions. The OPTI-AML trial led by @beatalleukemia funded by @LLSusa #BEATAML is investigating whether Aza/Ven x 14 days is = Aza/Ven x 28 days. https://t.co/D8xFeTZU4F https://t.co/jNwkR2zTyf
-
-
Mashup Score: 0
The addition of quizartinib to standard chemotherapy with or without allo-HCT, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival in adults aged 18ā75 years with FLT3-ITD-positive newly diagnosed AML. Based on the results from the QuANTUM-First trial, quizartinib provides a new, effective, and generally well tolerated treatment option for adult patients with FLT3-ITD-positive newly diagnosed AML.
Source: www.thelancet.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Leukemia Journal Club @UNC_Lineberger- the best scientific discussions always occur at happy hour. Grateful for such an amazing group of colleagues- we dissected Quantum-First in comparison to existing data w/ 7+3+Midostaurin. https://t.co/kVA7OMdnuN https://t.co/uKsfak8Uq4
-
-
Mashup Score: 1Counting Her Chickens: Catherine C. Coombs, MD | ASH Clinical News | American Society of Hematology - 2 year(s) ago
Catherine C. Coombs, MD How did you get started raising chickens? I did my fellowship training at Memorial Sloan Kettering Cancer Center in Manhattan. I had the best mentors and the best training there, but I completely hated living in Manhattan. Iāve always been an outdoorsy person and I looked forward to moving out of the city. When I would fantasize about what my life would be like as an…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Excited to see @calliecoombsmd interviewed in this monthās @ASHClinicalNews talking about her passion for š. My youngest son even made a cameo on her zoom screen- Iāll tell him he is now famous š! @ASH_hematology https://t.co/SDcFsTbP0k
-
-
Mashup Score: 2Combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Azacitidine/Venetoclax - 2 year(s) ago
Abstract. The BCL-2 inhibitor Venetoclax (VEN) in combination with Azacitidine (5-AZA) is currently transforming Acute Myeloid Leukemia (AML) therapy. However, there is a lack of clinically relevant biomarkers that predict response to 5-AZA/VEN. Here, we integrated transcriptomic, proteomic, functional and clinical data to identify predictors of 5-AZA/VEN response. Although cultured monocytic AML…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Truly elegant work published in @CD_AACR- a flow-based score of apoptosis regulators (MAC) can predict for response to Aza/Ven in #AML. Score only relevant in LSC-like cells. This is potentially impactful & exactly what we need in AML. Kudos to authors š https://t.co/D7fVPE5r2A
-
-
Mashup Score: 0Venetoclax + Azacitidine vs. Induction Chemotherapy in AML - Full Text View - ClinicalTrials.gov - 2 year(s) ago
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Long-term outcomes (as presented by @PratzKW) w/ Aza/Ven compelling but limited data on ācurativeā potential. Aza/Ven predicated on indefinite Tx (for now). We need randomized data & commend Amir Fathi @MGHCancerCenter for leading this important trial https://t.co/0TgLKa4nip
-
-
Mashup Score: 2
Revumenib, a potent and selective oral inhibitor of the menināKMT2A interaction, is associated with a low frequency of treatment-related adverse eventsĀ and promising clinical activity in patients with relapsed or refractory acute leukaemia.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
A new wave of 'targeted therapy' in #AML? Revumenib- oral menin inhibitor- in R/R AML w/ NPM1mut or KMT2Ar published in @Nature. Clinical activity striking- 30% CR/CRh in heavily pre-Tx R/R AML. Median time to response = 2 months/median DOR = 9 months. https://t.co/Fceg5GWoIV
-
Leukemia Journal Club Happy Hour tackled maintenance therapy with oral Azacitidine in NPM1 mutated AML patients- subset analyses from QUAZAR study- Great discussion with colleagues over šŗ @UNC_Lineberger https://t.co/vFNcO3OHdR https://t.co/28rRiu9mme